We are live on ! Find out more
UNCY icon

Unicycive Therapeutics
UNCY

30 hedge funds and large institutions have $27.4M invested in Unicycive Therapeutics in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

50% more funds holding

Funds holding: 20 → 30 (+10)

11% more capital invested

Capital invested by funds: $24.6M → $27.4M (+$2.8M)

5.1% less ownership

Funds ownership: 40.69% → 35.59% (-5.1%)

Holders
30
Holders Change
+10
Holders Change %
+50%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
9
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$2.85M
2
Squarepoint
Squarepoint
New York
+$511K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$292K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$231K
5
Goldman Sachs
Goldman Sachs
New York
+$197K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$104K
2
Renaissance Technologies
Renaissance Technologies
New York
-$56.2K
3
Lazard Asset Management
Lazard Asset Management
New York
-$55K
4
ACP
Acuta Capital Partners
California
-$12.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$7.8M +$2.85M +652,901 +57%
OCA
2
Octagon Capital Advisors
New York
$4.36M – – –
NCM
3
Nantahala Capital Management
Connecticut
$4.09M – – –
GPP
4
Great Point Partners
Connecticut
$3.47M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.87M +$231K +52,925 +9%
LGM
6
Logos Global Management
California
$2.06M +$4 +1 +0%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$548K +$292K +66,941 +114%
Squarepoint
8
Squarepoint
New York
$512K +$511K +117,327 New
ACP
9
Acuta Capital Partners
California
$262K -$12.7K -2,914 -5%
State Street
10
State Street
Massachusetts
$239K +$184K +42,304 +338%
Goldman Sachs
11
Goldman Sachs
New York
$197K +$197K +45,200 New
Citadel Advisors
12
Citadel Advisors
Florida
$182K +$182K +41,674 New
XT
13
XTX Topco
Cayman Islands
$165K +$165K +37,823 New
BlackRock
14
BlackRock
New York
$159K +$158K +36,355 New
Northern Trust
15
Northern Trust
Illinois
$143K +$95.5K +21,912 +203%
CPIG
16
Chicago Partners Investment Group
Illinois
$127K +$118K +26,961 New
CSS
17
Cubist Systematic Strategies
Connecticut
$104K +$104K +23,947 New
Morgan Stanley
18
Morgan Stanley
New York
$46.3K +$41.9K +9,612 +961%
Citigroup
19
Citigroup
New York
$29.2K +$29.2K +6,692 New
UBS Group
20
UBS Group
Switzerland
$23.7K +$23.7K +5,445 New
Bank of America
21
Bank of America
North Carolina
$3.61K +$3.33K +763 +1,192%
SS
22
SBI Securities
Japan
$2.44K +$31 +7 +1%
Rockefeller Capital Management
23
Rockefeller Capital Management
New York
$2.18K +$2.18K +500 New
TFM
24
TFC Financial Management
Massachusetts
$1.31K +$1.31K +300 New
FFO
25
Fortitude Family Office
Arizona
$467 +$466 +107 New
1
2

UNCY Hedge Fund Activity: Q3 2025 in Review

30 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2025, worth a combined $27.4M — up 11% from $24.6M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new UNCY positions and 3 closed out — a net gain of 10 holders — while 9 added to existing stakes and 1 trimmed.

The largest buyer was Vivo Capital, adding an estimated $2.85M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $104K sold.

  • 30 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2025, up from 20 in Q2 2025.
  • Funds reported $27.4M of Unicycive Therapeutics stock for Q3 2025, up 11% quarter-over-quarter.
  • 13 funds opened new Unicycive Therapeutics positions in Q3 2025 and 3 closed out, a net change of +10 holders.
  • The largest Unicycive Therapeutics buyer in Q3 2025 was Vivo Capital, an estimated $2.85M added.
  • The largest Unicycive Therapeutics seller in Q3 2025 was JP Morgan Chase, an estimated $104K sold.

Based on aggregated 13F filings for Q3 2025.